Danone and Chobani Lock Horns Over Protein Labeling

The legal challenge targets Chobani’s 20G Protein line, which Danone identifies as a direct competitor to its own Oikos Pro brand. According to the French dairy giant, Chobani is misleading consumers by manipulating serving sizes on labels to project higher protein content, a tactic it claims allows the New York-based company to undercut the pricing of the €1 billion Oikos portfolio. Chobani CEO Hamdi Ulukaya dismissed the allegations as a desperate attempt to generate negative headlines, asserting that his company never adds external protein to its products.

This conflict unfolds against a backdrop of shifting consumer habits driven by the rise of GLP-1 medications. Boston Consulting Group research indicates that yogurt is among the few food categories experiencing a sustained boost from patients seeking muscle-preserving nutrition both during and after their treatment. While Danone struggles to scale production to meet this surge, Barclays analysts have pointed to a loss of momentum for the firm’s U.S. dairy business. Market data from NielsenIQ confirms a clear divergence: Chobani’s U.S. market share climbed to 26% in the first quarter of this year, while Danone’s stake retreated to 25.8%.

Industry observers suggest the lawsuit is less about consumer protection and more about competitive frustration. Former Chobani executive Brad Charron noted that Danone has repeatedly targeted his former employer with legal action over the years, often to little effect. With Danone’s shares down 15% this year, the company faces mounting pressure to regain its footing in a category where Chobani is currently growing at a rate exceeding 20%.